Difference between revisions of "Carmustine (BCNU)"

Revision as of 01:20, 27 June 2024

General information

Class/mechanism: Nitrosourea, alkylates DNA and RNA, inhibits several key enzymatic processes by carbamoylation of amino acids in proteins.^[1]^[2]
Route: IV
Extravasation: vesicant/irritant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, UpToDate Lexidrug, UpToDate (courtesy of Lexicomp), or the prescribing information.^[1]

Diseases for which it is established (work in progress)

Peripheral T-cell lymphoma

Diseases for which it is used

Diseases for which is was used

Patient drug information

History of changes in FDA indication

1977-03-07: Initial FDA approval
2007-08-17 (oldest label available at Drugs @ FDA): indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in brain tumors: glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. (No supporting studies are cited)
2007-08-17 (oldest label available at Drugs @ FDA): indicated as palliative therapy for multiple myeloma in combination with prednisone. (No supporting studies are cited)
2007-08-17 (oldest label available at Drugs @ FDA): indicated as palliative therapy for Hodgkin’s Disease as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy. (No supporting studies are cited)
2007-08-17 (oldest label available at Drugs @ FDA): indicated as palliative therapy for Non-Hodgkin’s lymphomas as secondary therapy in combination with other approved drugs for patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy. (No supporting studies are cited)

History of changes in EMA indication

1974-04-23: EURD

Also known as

Generic names: BCNU, bischloroethylnitrosourea, carmustin
Brand names: Becenun, BiCNU, Carmubris, Leucerom, Nitrourean, Nitrumon

References

[insert-1] 1.0 ^1.1 ^1.2 Carmustine (BiCNU) package insert

[2] Carmustine (BiCNU) package insert (locally hosted backup)

[3] Carmustine (BiCNU) patient drug information (Chemocare)

[4] Carmustine (BiCNU) patient drug information (UpToDate)

[1]

[2]

[3]

[4]

@@ Line 4: / Line 4: @@
 <br>Extravasation: [[vesicant]]/[[irritant]]
-For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
+For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>
 ==Diseases for which it is established ''(work in progress)''==